765 related articles for article (PubMed ID: 30770740)
1. EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC.
Yin Y; Sun M; Zhan X; Wu C; Geng P; Sun X; Wu Y; Zhang S; Qin J; Zhuang Z; Liu Y
J Exp Clin Cancer Res; 2019 Feb; 38(1):83. PubMed ID: 30770740
[TBL] [Abstract][Full Text] [Related]
2. JQ1 and PI3K inhibition synergistically reduce salivary adenoid cystic carcinoma malignancy by targeting the c-Myc and EGFR signaling pathways.
Liu X; Wu H; Huang P; Zhang F
J Oral Pathol Med; 2019 Jan; 48(1):43-51. PubMed ID: 30269363
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
[TBL] [Abstract][Full Text] [Related]
4. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
5. Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression.
Li GQ; Guo WZ; Zhang Y; Seng JJ; Zhang HP; Ma XX; Zhang G; Li J; Yan B; Tang HW; Li SS; Wang LD; Zhang SJ
Oncotarget; 2016 Jan; 7(3):2462-74. PubMed ID: 26575167
[TBL] [Abstract][Full Text] [Related]
6. BET bromodomain inhibition of MYC-amplified medulloblastoma.
Bandopadhayay P; Bergthold G; Nguyen B; Schubert S; Gholamin S; Tang Y; Bolin S; Schumacher SE; Zeid R; Masoud S; Yu F; Vue N; Gibson WJ; Paolella BR; Mitra SS; Cheshier SH; Qi J; Liu KW; Wechsler-Reya R; Weiss WA; Swartling FJ; Kieran MW; Bradner JE; Beroukhim R; Cho YJ
Clin Cancer Res; 2014 Feb; 20(4):912-25. PubMed ID: 24297863
[TBL] [Abstract][Full Text] [Related]
7. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
[TBL] [Abstract][Full Text] [Related]
8. Co-inhibition of BET proteins and NF-κB as a potential therapy for colorectal cancer through synergistic inhibiting MYC and FOXM1 expressions.
Wu T; Wang G; Chen W; Zhu Z; Liu Y; Huang Z; Huang Y; Du P; Yang Y; Liu CY; Cui L
Cell Death Dis; 2018 Feb; 9(3):315. PubMed ID: 29472532
[TBL] [Abstract][Full Text] [Related]
9. Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer.
Leal AS; Williams CR; Royce DB; Pioli PA; Sporn MB; Liby KT
Cancer Lett; 2017 May; 394():76-87. PubMed ID: 28254412
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer.
Bonazzoli E; Predolini F; Cocco E; Bellone S; Altwerger G; Menderes G; Zammataro L; Bianchi A; Pettinella F; Riccio F; Han C; Yadav G; Lopez S; Manzano A; Manara P; Buza N; Hui P; Wong S; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Schlessinger J; Santin AD
Clin Cancer Res; 2018 Oct; 24(19):4845-4853. PubMed ID: 29941483
[No Abstract] [Full Text] [Related]
11. MYC-targeted WDR4 promotes proliferation, metastasis, and sorafenib resistance by inducing CCNB1 translation in hepatocellular carcinoma.
Xia P; Zhang H; Xu K; Jiang X; Gao M; Wang G; Liu Y; Yao Y; Chen X; Ma W; Zhang Z; Yuan Y
Cell Death Dis; 2021 Jul; 12(7):691. PubMed ID: 34244479
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of BET bromodomain targets genetically diverse glioblastoma.
Cheng Z; Gong Y; Ma Y; Lu K; Lu X; Pierce LA; Thompson RC; Muller S; Knapp S; Wang J
Clin Cancer Res; 2013 Apr; 19(7):1748-59. PubMed ID: 23403638
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
[TBL] [Abstract][Full Text] [Related]
14. Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer.
Enomoto K; Zhu X; Park S; Zhao L; Zhu YJ; Willingham MC; Qi J; Copland JA; Meltzer P; Cheng SY
J Clin Endocrinol Metab; 2017 Jul; 102(7):2268-2280. PubMed ID: 28368473
[TBL] [Abstract][Full Text] [Related]
15. Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells.
Tögel L; Nightingale R; Chueh AC; Jayachandran A; Tran H; Phesse T; Wu R; Sieber OM; Arango D; Dhillon AS; Dawson MA; Diez-Dacal B; Gahman TC; Filippakopoulos P; Shiau AK; Mariadason JM
Mol Cancer Ther; 2016 Jun; 15(6):1217-26. PubMed ID: 26983878
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
[TBL] [Abstract][Full Text] [Related]
17. Targeting c-Myc: JQ1 as a promising option for c-Myc-amplified esophageal squamous cell carcinoma.
Wang J; Liu Z; Wang Z; Wang S; Chen Z; Li Z; Zhang M; Zou J; Dong B; Gao J; Shen L
Cancer Lett; 2018 Apr; 419():64-74. PubMed ID: 29366803
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple-negative breast cancer.
Park IH; Yang HN; Jeon SY; Hwang JA; Kim MK; Kong SY; Shim SH; Lee KS
Sci Rep; 2019 Sep; 9(1):13305. PubMed ID: 31527644
[TBL] [Abstract][Full Text] [Related]
19. Activation of EGFR-KLF4 positive feedback loop results in acquired resistance to sorafenib in hepatocellular carcinoma.
Pang L; Xu L; Yuan C; Li X; Zhang X; Wang W; Guo X; Ouyang Y; Qiao L; Wang Z; Liu K
Mol Carcinog; 2019 Nov; 58(11):2118-2126. PubMed ID: 31465134
[TBL] [Abstract][Full Text] [Related]
20. BET protein inhibitor JQ1 attenuates Myc-amplified MCC tumor growth in vivo.
Shao Q; Kannan A; Lin Z; Stack BC; Suen JY; Gao L
Cancer Res; 2014 Dec; 74(23):7090-102. PubMed ID: 25277525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]